You are here » Home » About CMT » What is CMT »  Classification of CMT

Classification of CMT

The following is a summary of the current understanding of the genetic classification of CMT.

The key point to remember is that there are two main forms of CMT:

Demyelinating (CMT1) – affects the myelin sheath insulating and nourishing the nerve’s axon.

Axonal (CMT2) – directly affects the axon.

The rest of the various classifications are all variations of these two main groups and, currently, will have no impact on the management of the condition.

 

 

CMT Type 1

With the exception of Type 1X, which is inherited through the X Chromosome, CMT Type 1 is inherited in an autosomal dominant pattern. CMT Type 1 accounts for more than two-thirds of all cases of CMT.

Type 1A

This is the most common form of CMT, comprising at least 60 percent of all patients with CMT Type 1. The disorder is caused by a duplication of the PMP22 gene on Chromosome 17. Instead of having two copies of the gene (one of each paired chromosome), there are three copies, two on one chromosome and one on the other. PMP22 is a peripheral myelin protein, but its exact function in causing CMT is still not known. It is inherited in an autosomal dominant fashion.

CMT1A usually presents with a typical CMT phenotype (clinical presentation). Patients are slow runners in childhood, develop high arches, hammertoes and often require orthotics (braces) for ankle support. Varying degrees of hand weakness occur, often appearing as much as ten years after foot and leg problems. Problems with balance because of ankle weakness and loss of proprioception are common. Most patients remain ambulatory throughout life and life expectancy is normal.

Type 1B
This type is caused by a defect of the MPZ gene on chromosome 1. Again, MPZ is peripheral myelin protein, but its role is not known. Type 1B is an autosomal dominant disorder. Patients with 1B have a somewhat typical phenotype, but often with more pronounced calf wasting. There is a wide range of severity within Type 1B, from very severe forms such as Dejerine-Sottas (infantile onset) to milder cases with onset much later in life. (More than one type of CMT may be referred to as Dejerine-Sottas since the term refers to an age of onset of less than three years rather than to a unique genetic defect.)

Type 1C
Researchers at the University of Washington have recently identified the locus of Type 1C as Chromosome 16, the LITAF/SIMPLE gene. Type 1C is also autosomal dominant in inheritance. There is limited clinical information on patients with 1C, but they develop distal weakness, atrophy, and sensory loss and have slow nerve conduction velocity scores.

Type 1D
This type is caused by an early growth response protein 2, known as ERG2, found on Chromosome 10. Inheritance is autosomal dominant. Most cases of 1D are severe, such as Dejerine-Sottas, while a few have milder phenotypes presenting later in life.

Type 1F
Type 1F accounts for a very small percentage of cases. It is an autosomal dominant form of CMT in which the defect is on Chromosome 8 and the neurofilament light chain protein.

Type 1X
This second most common of form of CMT, accounting for 10-16 percent of all cases is found on the X Chromosome, one of sex chromosomes. The flaw is caused by a gap junction beta 1 protein connected to connexin 32. Typically, this form has onset in adolescence or childhood and often affects males more severely than females. An affected male with CMT1X cannot pass the defect to his son, but will pass it to all his daughters. An affected female has a 50% chance of passing the mutation to either her sons or her daughters.

 

CMT Type 2

CMT Type 2 represents axonal forms that are dominantly inherited and make up about one-third of all dominant CMT cases. The clinical presentation is similar to Type 1: distal weakness, muscle atrophy, sensory loss and foot deformities. Patients with Type 2 have a wider age range for onset of the disorder and more variation in degree of disability. They are slightly more likely to maintain their deep tendon reflexes.

Type 2A
The defect causing CMT 2A is found on chromosome 1p36 at the MFN2 gene. This gene is mutated and is involved in the fusion of mitochondria, the metabolic engines of the cells. This type of CMT is often severe and can include optic atrophy.

Type 2B
Type 2B is characterized by severe ulceration problems and the defect is located on chromosome 3, the RAB 7 protein. CMT 2B is predominantly a sensory disorder and there is some thought that it is not really CMT, but a pure sensory neuropathy.

Type 2C
This type is a very rare form in which patients may have diaphragm or vocal cord paresis in addition to the other problems of CMT. Linkage to chromosome 12 has been found.

Type 2D
The CMT 2D locus is on chromosome 7p14 and the genetic cause has been identified as mutations in the glycyl RNA synthetase gene. CMT 2D is a confusing disorder because some patients have sensorimotor neuropathies, while others have only motor symptoms.

Type 2E
CMT type 2E has been established with linkage to chromosome 8p21 and studies have identified mutations in the neurofilament light gene.

 

CMT Type 3

Type 3 is a particularly severe variant. The term Dejerine-Sottas syndrome (DSS) is used to describe patients who are severely disabled and develop CMT in infancy. This term was coined before the genetic causes of CMT were identified. As a result, the usage of this term is somewhat confusing. Dejerine-Sottas was originally thought to be a severe and disabling neuropathy beginning in infancy with an autosomal recessive inheritance pattern. Recently, it has been shown that DSS patients also have autosomal dominant mutations of PMP22, MPZ, EGR2 and even PRX and GDAP. Most patients with DSS have extremely slow nerve conduction velocities. Most children with DSN have severe demyelination while others show predominantly axonal loss when sural nerve biopsies are done. Currently, the term Dejerine-Sottas is used to define patients who have onset by 3 years of age, delayed motor milestones, and severe motor, sensory and skeletal defects.

Congenital hypomyelination (CH) is a term originally used to describe peripheral nerves that were so abnormal that they suggested a developmental failure of the peripheral nervous system myelination. Patients with CH were hypotonic within the first year of life, had developmental delays in walking and had swallowing or respiratory difficulties. Some patients with CH were considered “floppy” infants. It is difficult to distinguish between DSS and CH since both have severe pathological changes on sural nerve biopsies and both have very slow nerve conduction velocities.

 

CMT Type 4

All Type 4 instances of CMT are inherited in an autosomal recessive pattern and are considered rare. They have various phenotypical presentations but are more severe than autosomal dominantly inherited disorders. These disorders often have systemic symptoms, such as cataracts and deafness. CMT 4A and B are demyelinating and 4C is axonal.

Type 4A
CMT Type 4 is linked to Chromosome 8 and is caused by mutations in the GDAP 1 protein, of unknown function. This form was first described in four families in Tunisia who were highly inbred. Clincial onset began at age 2 with delayed developmental milestones of sitting or walking. Many patients are wheelchair dependent by the end of the first decade of life. Hoarse voice and vocal cord paresis have been reported.

Type 4B
The genetic location for the defect causing Type 4B is on chromosome 11 and presents with focally folded myelin sheaths in nerve biopsies. Affected patients become symptomatic early in life, with an average age of onset at 34 months. Unlike most types of CMT, both proximal and distal weakness is common.

Type 4C
Type 4C is a childhood onset form of hereditary motor and sensory neuropathy (HSMN) with early onset scoliosis. The protein defect defines a new family of unknown function.

Type 4D
This form was first described as a separate disorder with linkage to Chromosome 8 in a Gypsy population with autosomal recessive inheritance. The clinical features included distal weakness, muscle wasting and sensory loss, foot and hand deformities and loss of deep tendon reflexes. Deafness is always found in these patients and occurs by the third decade. Nerve conduction is severely reduced in younger patients and completely unattainable after age 15.

Type 4F
CMT type 4F is a severe form of recessive CMT that has been defined in a large Lebanese family with mutations in the PRX gene on Chromosome 19. Nerve conduction studies are markedly slow and onion bulb formations are observed in nerve biopsies.

 

Information updated from www.cmtausa.org with thanks

 

GENE TABLE:

 Clinical type                     Inheritance   Locus / Gene

1. Demyelinating (CMT 1)

CMT 1A                           AD                 Duplication 17p11.2-12 / PMP-22  
                                                                                 17p11.2-12 / Point mutation PMP-22

CMT 1B                           AD                 1q22-q23 / Point mutation Po

CMT 1C                           AD                  16p13.1 - p12.3 / SIMPLE / LITAF

CMT 1D                           AD                  10q21-q22 / Point mutation EGR2

Charcot-Marie-Tooth type 1 x-linked (CMT X)

CMT X                             X-linked          Xq13.1 / Point mutation Cx32

Dejerine-Sottas disease (HMSN III)

DSD A                             AD (AR)          17p11.2-12 / Point mutation PMP-22

DSD B                             AD (AR)          1q22-q23 / Point mutation Po

DSD C                            AD                    10q21-q22 / Point mutation EGR2

Congenital hypomyelinating neuropathy (CHN)

CHN A                           AD                    17p11.2-12 / Point mutation PMP-22

CHN B                           AD                    1q22-q23 / Point mutation Po

CHN C                           AD (AR)           10q21-q22 / Point mutation EGR

Hereditary neuropathy with liability to pressure palsies (HNPP)

HNPP A                         AD                    Deletion 17p11.2 / PMP-22 17p11.2-                                                                                     12 / Point mutation PMP-22

Charcot-Marie-Tooth type 1 autosomal recessive (CMT1 AR)

CMT1 ARA (CMT4A)   AR                    8q13 - 21.1/ GDAP1

CMT1 ARB1 (CMT4B1)   AR                11q22 / MTMR2

CMT1 ARB2 (CMT4B2)   AR                11p15 / MTMR13

CMT1 ARC (CMT 4C)     AR                 5q23-q33 / KIAA1985

CMT1 ARD (CMT4D / HMSNL) AR      8q24 / NDRG1

CMT1 ARE (CCFDN)      AR                 18q

CMT1 ARF (CMT4F)      AR                  19q13.1-13.3 / Periaxin

CMT1 ARG (HMSNR)    AR                   10q22-q

2. Axonal (CMT 2) Charcot-Marie-Tooth type 2 autosomal dominant (CMT 2 / HMSN II)

CMT 2A                          AD                 1p35-KIF1B                                           
                                                                                            / GTPase mitofusin 2

CMT 2B                          AD                    3q13 – q22 / RAB7

CMT 2C                         AD                     12q23 – q24

CMT 2D                         AD                     7p14 / GARS

CMT 2E                         AD                     8p21 / NF-L

CMT 2F                         AD                     7q11-q21 / HSP 27

CMT 2G                        AD                     12q12-q13.3

CMT 2L                        AD                     12q24 / HSP 22

CMT 2                          AD                     1q22-q23 / Point mutation Po

CMT 2 (HMSNP)         AD                       3q13.1

Charcot-Marie-Tooth type 2 x-linked (CMT 2X)

CMT 2X                       X-linked              Xq24 – q26

Charcot-Marie-Tooth type 2 autosomal recessive (CMT2 AR)

CMT2 AR                    AR                      1q21.2 – 21.3 / LMNA

CMT2 AR                    AR                      19q13.1

CMT2 AR                    AR                      8q21 / GDAP1 3.

3  Dominant Intermediate CMT (DI-CMT)

DI-CMTA                   AD                       10q24.1-q25.1

DI-CMTB                   AD                        Dynamin 2

DI-CMTC                   AD                           1p34-p35

 

AD - autosomal dominant 
AR - autsomal recessive

 

With thanks to Dr Mary Reilly, Consultant Neurologist from the National Hospital for Neurology, London

 

References:

Charcot–Marie–Tooth disease, Kinga Szigeti and James R Lupski

Eur J Hum Genet. 2009 June; 17(6): 703–710.

Published online 2009 March 11. doi:  10.1038/ejhg.2009.31
PMCID: PMC2947101



Date updated - 21/05/2013 

Member zone



Forgot your username or password?

donate.png